ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0200

Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials

Maria Bacalao1, Marie Maitre2 and Shivani Kottur3, 1UT Southwestern, Dallas, TX, 2Parkland Hospital, Dallas, TX, 3UT Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2024

Keywords: Access to care, clinical trial, Disparities

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Health Services Research – ACR/ARP Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Healthcare disparities in SLE clinical trials are well known, with minoritized individuals facing more significant SLE morbidity and mortality, while being underrepresented in randomized clinical trials (RCTs). However, we have limited information as to how to best recruit a diverse group of participants to SLE clinical trials. Barriers to clinical trial participation can originate both with the patients or with their clinicians. We therefore sought to investigate the effectiveness of educational curriculums at decreasing such barriers by improving the knowledge, skills and attitudes regarding clinical trial participation in both groups.

Methods: We collaborated with the American College of Rheumatology, the Lupus Research Alliance, and the Lupus Association to develop educational curriculums for both clinicians and patients to see if we could improve their knowledge, attitudes, and skills regarding clinical trial participation.  Workshops lasted approximately 90 minutes for each group and had virtual and in-person options available. Participants were surveyed immediately before, immediately after and one month after the workshop to assess these domains. Data were analyzed using the Wilcoxson signed rank test and the T test for continuous variables and the McNemar’s test for categorical variables using SAS.

Results: 32 clinicians (physicians, fellows, advanced practice providers and RNs) participated in the clinician workshop, and 45 SLE patients participated in the patient workshop. Attitudes towards clinical trials were highly favorable among patients and clinicians prior to the workshop and remained positive afterwards. The workshops increased the patients’ comfort level regarding clinical trial participation and the protective benefits of the IRBs, and showed more interest for participating in a clinical trial. Clinicians reported comfort with the clinical trial process and how to refer patients to clinical trials. They also reported that they intended to discuss clinical trials more frequently with their patients. Regarding knowledge about clinical trials, the results were mixed. Clinicians reported an increased knowledge regarding protections afforded to patients in RCTs and SLE disparities, but knowledge about the historical and regulatory aspects of RCTs did not significantly improve.  There was a significant increase in the patients’ knowledge regarding the protections afforded to them in clinical trials, but there was no significant change in their understanding of placebo and alternatives to clinical trial participation. However, these improvements did not translate into increasing patient enrollment into RCTs or research registries.

Conclusion: Although our study did increase both patients’ and clinicians’ skill and comfort level regarding RTC participation, its small size did not allow us to observe any concrete gains in RTC enrollment.  This is a low-cost easily scalable solution, and larger studies done across different institutions could be done to conclusively answer whether educational initiatives have tangible benefits in patient recruitment.

Supporting image 1

Table 1: Patients’ Attitudes Regarding Clinical Trials (Likert Scale Means) (1-5 Likert Scale, 5 being the most favorable)

Supporting image 2

Table 2: Patients’ Attitudes Regarding Clinical Trials (Yes/No)

Supporting image 3

Table 3: Clinician’s Attitudes Regarding Clinical Trials


Disclosures: M. Bacalao: GlaxoSmithKlein(GSK), 1; M. Maitre: None; S. Kottur: None.

To cite this abstract in AMA style:

Bacalao M, Maitre M, Kottur S. Evaluating the Effectiveness of Educational Initiatives on Recruiting Underrepresented Participants into SLE Clinical Trials [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluating-the-effectiveness-of-educational-initiatives-on-recruiting-underrepresented-participants-into-sle-clinical-trials/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-the-effectiveness-of-educational-initiatives-on-recruiting-underrepresented-participants-into-sle-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology